Creatine for Brain Health: What the New Meta-Analyses Actually Show

← Back to articles

Creatine monohydrate has been a fixture in sports supplements for decades. In the last five years, research has expanded well beyond muscle — into the brain. Creatine is not just a fuel source for muscle contractions. It also plays an important role in brain energy metabolism, where phosphocreatine (a stored form of energy) helps keep ATP (the cell's main energy currency) available during demanding mental tasks. Two recent meta-analyses — Prokopidis and colleagues in Nutrition Reviews (2023) and Xu and colleagues in Frontiers in Nutrition (2024) — have pulled together the human trial data on creatine and cognition. The findings have implications for a much wider group than the typical creatine user.

How Creatine Works in the Brain

The brain is an expensive organ. It uses about 20% of the body's energy while making up only 2% of body weight. Neurons rely on ATP for almost every function — running ion pumps, sending signals across synapses, making neurotransmitters, and general cellular housekeeping. During intense mental work — hard problem-solving, sustained attention, or holding several items in mind at once — local ATP demand can spike fast. The creatine-phosphocreatine system helps meet that demand faster than the body's slower main energy pathway (oxidative phosphorylation) can on its own.

Unlike muscle, the brain makes some of its own creatine using two enzymes called AGAT and GAMT. But that internal supply is limited, and supplementation can still push brain creatine higher. Magnetic resonance spectroscopy (an MRI-based technique that can measure brain chemistry) has shown that taking creatine raises brain creatine levels by about 5–10% in healthy adults. The increase is larger in vegetarians and vegans, who get less creatine from their diet to begin with.

The New Meta-Analyses: What They Found

The 2023 Prokopidis meta-analysis pooled 16 randomized controlled trials (492 healthy participants) testing creatine on memory. It found a small but statistically significant improvement in memory performance with creatine, with a standardized mean difference (SMD — a standard effect-size measure) of about 0.30. Older adults aged roughly 66–76 showed larger effects than younger adults. The 2024 Xu meta-analysis added more trials focused on general cognition and found similar results, with effects most consistent in older adults and in conditions of mental stress.

• Working memory: The most consistent effect was in tasks that require you to hold and manipulate information in real time. Effect sizes were small to moderate but consistent across age groups.
• Executive function: Planning, task-switching, and inhibitory control improved, especially in older adults (60+), where effect sizes were larger.
• Processing speed: Improvements in reaction time and processing speed showed up mostly under cognitive stress — sleep deprivation, mental fatigue, low oxygen — rather than at rested baseline.
• Subgroup effects: Vegetarians and older adults consistently showed the largest benefits. Both groups tend to start with lower brain creatine, leaving more room for supplementation to matter.

The classic physical loading protocol (20 g/day for 5 days) was not meaningfully better than a maintenance dose (3–5 g/day) for cognitive outcomes. Tissue saturation builds more slowly on the lower dose, but reaches similar levels within about 4 weeks.

Creatine and Neuroprotection

Beyond short-term cognition, preclinical and early human evidence suggests creatine may help protect neurons against damage from traumatic brain injury (TBI), loss of blood flow (ischemia), and certain degenerative processes. The proposed mechanisms include:

• Stabilizing mitochondrial membrane potential during energy stress, reducing the chance of programmed cell death
• Buffering against glutamate-driven excitotoxicity, a damage pathway seen in TBI and stroke
• Helping maintain ion gradients during energy failure, reducing dangerous neuronal firing

In children with traumatic brain injury, a small open-label study by Sakellaris and colleagues (2006 and 2008 follow-up) reported that creatine supplementation (0.4 g/kg/day for 6 months) shortened the duration of post-traumatic headache, dizziness, and fatigue compared with standard care. Larger controlled trials in adults are still underway. In Parkinson's disease, the NIH-funded Phase 3 NET-PD LS-1 trial (Kieburtz and colleagues, 2015) found creatine at 10 g/day safe and well-tolerated but did not slow clinical progression. Some researchers have since argued the dose may have been too low for a large-body, long-half-life pool like the brain.

Depression and Mood: An Emerging Signal

A less expected finding is that creatine may boost the effect of antidepressants. A 2012 RCT by Lyoo and colleagues in the American Journal of Psychiatry reported that adding 5 g/day of creatine to SSRI therapy in women with major depressive disorder produced a faster and larger response than SSRI alone. The proposed mechanism involves creatine fixing an energy shortfall in the prefrontal cortex seen in depression on phosphorus-31 MRS imaging.

A 2023 narrative review in Translational Psychiatry concluded that the evidence for creatine as an antidepressant add-on is preliminary but promising, with particular interest in treatment-resistant cases. Larger trials are still needed before clinical practice changes, but the signal adds to the picture of creatine as neurologically active, not just a muscle supplement.

Safety and Practical Guidance

Creatine monohydrate has an exceptional long-term safety profile. Over three decades of research have not shown kidney damage in healthy people at standard doses. A common source of confusion is serum creatinine — a breakdown product of creatine used to estimate kidney function — which does tend to rise slightly on blood panels when someone takes creatine. That rise reflects the extra creatine in the body, not kidney injury. Actual kidney function markers (such as estimated GFR from cystatin C) remain normal, as shown in systematic reviews including Dolan and colleagues in Nutrition Reviews (2019).

• Recommended dose: 3–5 g/day of creatine monohydrate, taken at any time of day (pre-workout timing adds little for cognitive benefit)
• Loading: Not needed for cognitive benefit; steady-state brain creatine levels are reached in about 4 weeks at 3–5 g/day
• Form: Monohydrate is the most tested and cheapest; no credible evidence that HCl, ethyl ester, or buffered forms perform better
• Cautions: Pre-existing kidney disease (discuss with your physician); not recommended during pregnancy (insufficient data)